Erythromycin ( DrugBank: Erythromycin )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
36	Epidermolysis bullosa	2
164	Oculocutaneous albinism	1
228	Bronchiolitis obliterans	1
291	Hirschsprung disease, entire colon type	1

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02005029 (ClinicalTrials.gov)	April 2013	18/9/2013	Erythromycin in Parkinson's Disease	Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics	Parkinson's Disease;Levodopa	Drug: Erythromycin;Drug: placebo	Virginia Commonwealth University	NULL	Completed	18 Years	80 Years	All	18	N/A	United States

36. Epidermolysis bullosa

---

Clinical trials : 160 /  Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01340235 (ClinicalTrials.gov)	June 2011	11/4/2011	Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin	Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin	Epidermolysis Bullosa	Drug: Oral erythromycin	Centre Hospitalier Universitaire de Nice	NULL	Recruiting	6 Months	8 Years	Both	8	Phase 3	France
2	EUCTR2010-024428-10-FR (EUCTR)		03/02/2011	Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale	Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale	Dowling Maera's bullous epidermolysis is a génodermatose with autosomique dominant transmission owed to transfers of the genes coding for keratins. It results from it a cutaneous fragility very severe especially during the early childhood. Tetracyclines showed a certain efficiency in cases isolated probably by their anti-inflammatory action but cannot be used at the young child's. The érythromycine, used in the other inflammatory dermatosis, seems to be a good candidate for these patients. MedDRA version: 12.1;Level: LLT;Classification code 10056508;Term: Acquired epidermolysis bullosa	Trade Name: erythrocine Product Name: erythrocine oral Trade Name: erythromycine Product Name: erythrocine oral	CHU de NICE	NULL	NA			Female: yes Male: yes	8	Phase 2	France

164. Oculocutaneous albinism

---

Clinical trials : 15 /  Drugs : 57 - (DrugBank : 34) / Drug target genes : 35 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00467831 (ClinicalTrials.gov)	April 2007	28/4/2007	Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome	Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome	Hermansky-Pudlak Syndrome (HPS);Pulmonary Fibrosis;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Metabolic Disease	Drug: Losartan;Drug: Zileuton;Drug: N-Acetylcysteine;Drug: Pravastatin;Drug: Erythromycin	National Human Genome Research Institute (NHGRI)	NULL	Terminated	18 Years	70 Years	All	3	Phase 1/Phase 2	United States

228. Bronchiolitis obliterans

---

Clinical trials : 96 /  Drugs : 125 - (DrugBank : 34) / Drug target genes : 33 - Drug target pathways : 155

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00367419 (ClinicalTrials.gov)	November 2006	21/8/2006	Use of Erythromycin in Mustard-Induced Bronchiolitis	Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans	Bronchiolitis Obliterans;Acute Obliterating Bronchiolitis	Drug: Erythromycin	Baqiyatallah Medical Sciences University	NULL	Completed	N/A	N/A	Male		Phase 4	Iran, Islamic Republic of

291. Hirschsprung disease, entire colon type

---

Clinical trials : 14 /  Drugs : 35 - (DrugBank : 15) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03593252 (ClinicalTrials.gov)	September 1, 2018	22/5/2018	Bowel Preparation in Elective Pediatric Intestinal Surgery	Mechanical Bowel Prep and Prophylactic Oral Antibiotic Use in Children: Implications for Intestinal Surgery Complications	Colostomy Stoma;Ileostomy - Stoma;Jejunostomy Stoma;Hirschprung's Disease;NEC;Inflammatory Bowel Diseases;Meconium Ileus;Bowel Obstruction	Drug: Senna;Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid;Drug: Erythromycin;Drug: Kanamycin;Drug: Cefazolin;Drug: Metronidazole;Other: Nil per os	McMaster University	NULL	Not yet recruiting	6 Months	18 Years	All	48	N/A	NULL

Back to top